TITLE:
An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain

CONDITION:
Herpes Zoster

INTERVENTION:
Capsaicin Dermal Patch

SUMMARY:

      This study is an open-label, multicenter, extension study for subjects who completed
      NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks
      (up to +7days) before entry into Study C114
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Key Eligibility Criteria:

          -  Must have completed NeurogesX Study C111 and received treatment with NGX-4010
             (Capsaicin Patch) within 12 weeks (up to +7 days) before entry into Study C114.

          -  Demonstrated adherence to protocol requirements during Study C111, and willing and
             able to comply with protocol requirements for the duration of the study
             participation.

          -  Must not have had any serious adverse experience since enrollment in Study C111,
             whether or not considered to be study drug-related.

          -  Must have intact skin at the treatment area.

          -  Must be prepared to remain on the same pain medications at the same doses as before
             the study for the entire duration of the study (36 weeks).

          -  Must not use topical pain medications on painful areas.

          -  Must be at least 18 years old, not pregnant, and able to take care of self
             independently, with only occasional assistance if needed.

          -  No history or current problem with substance abuse.
      
